Moreover, we found that both THBS1- and TNC-activated integrin β1/mTOR signaling played a role in regulating chemotherapy resistance, suggesting that targeting integrin β1/mTOR pathway may be a promising therapeutic strategy to overcome chemotherapy resistance in breast cancer. The gene discussed is MTOR; the disease is breast carcinoma.